N/A N=1 Treatment

Treatment With Intravitreal Avastin for Large Uveal Melanomas

Uveal Melanoma

Bottom Line

View on ClinicalTrials.gov: NCT00596362 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2015

Primary outcome: Primary: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). — 1; 0; 0; 0 participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: AVASTIN (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Memorial Sloan Kettering Cancer Center
Primary completion: Jun 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume).	1; 0; 0; 0	—

Summary

The purpose of this study is to test the safety and effectiveness of Avastin introduced into the inside of the eyeball in causing shrinkage of the uveal melanoma (tumor of the eye). Avastin is an anti-cancer drug specially designed to shrink blood vessels within tumors.

Eligibility Criteria

Inclusion Criteria

Patients diagnosed with large uveal melanomas who elect to undergo enucleation.
Patients diagnosed with uveal melanomas with tumor thickness > 10 mm or basal diameter > 16 mm, as measured by ultrasound examination, funduscopic examination, or transillumination.

Exclusion Criteria

Cases that do not meet the above criteria for tumor size will be ineligible to participate in the study.
Patients with history of metastatic cancer (other than melanoma).
Patients not able to provide consent for the study.
Patients with clinical or radiographic evidence of extraocular extension of the tumor.
Patients with a previous history of an adverse reaction to intravitreal injection.
Patients with a poor view of the fundus due to cataract or vitreous hemorrhage.
Patients with intravitreal silicone oil or gas tamponade.
Patients < 18 years of age.
Women known to be pregnant.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00596362). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.